Christian Récher

OncoDaily

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

May, 2025

Christian Récher

Mar 2, 2025, 08:51 | Blog

Joshua Zeidner: Magrolimab plus Azacitidine vs Physician Choice in Newly Diagnosed TP53-mut AML

Joshua Zeidner, Associate Professor at UNC Lineberger, shared on X about recent paper he and…

Dec 23, 2024, 11:55 | Drugs

Talha Badar: Venetoclax and Azacitidine for elderly AML ineligible for intensive Induction

Talha Badar shared on X: “Brief overview of venetoclax+azacitidine for elderly AML ineligible for intensive…

Dec 6, 2024, 15:22 | Insight

The impact of post-remission G-CSF use in the phase 3 studies of venetoclax in AML

Mohamed Benlazar, Professor of Hematology at Sidi Bel Abbès University Hospital, shared a post on…

Aug 19, 2024, 10:07 | Insight

Nicolas Duployez: A 4-gene prognostic model stratified OS outcomes with VEN-AZA treatment in AML

Nicolas Duployez, Molecular Biologist at Lille University Hospital, shared on X about a recent paper…

Jul 9, 2024, 00:57 | Insight

Talha Badar: Outcome after stopping venetoclax and azacitidine

Talha Badar shared on X: “American Journal of Hematology, Blood Research Journal, Wiley Online Library.…

All: 5 Posts: 1 - 100

'

Who From Oncology is Featured in TIME100 Health 2025?

'

Francesco Acerbi and Testicular Cancer: The Defender's Fight and Triumphant Return to Football

'

Yvonne Award for Breakthrough Research 2024 Recipient to Time100 Health List

'

Dr Saunthari Somasundaram is the new President-Elect of the NCD Alliance

'

Does Plastic Cause Cancer? Myths and Facts

Special Coverage

Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023